JAMP-ASA 81MG EC TABLET (ENTERIC-COATED)
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
01-09-2022
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
ACETYLSALICYLIC ACID
Fáanlegur frá:
VITA HEALTH PRODUCTS INC
ATC númer:
B01AC06
INN (Alþjóðlegt nafn):
ACETYLSALICYLIC ACID
Skammtar:
81MG
Lyfjaform:
TABLET (ENTERIC-COATED)
Samsetning:
ACETYLSALICYLIC ACID 81MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
1000
Gerð lyfseðils:
OTC
Lækningarsvæði:
SALICYLATES
Vörulýsing:
Active ingredient group (AIG) number: 0101169013; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2014-07-30
Vara einkenni
Jamp - ASA 81 mg EC Page 1 of 46
PRODUCT MONOGRAPH
JAMP - ASA 81 MG EC
Acetylsalicylic
Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
Vita Health Products Inc.
150 Beghin Avenue
Winnipeg,
MB
Canada R2J 3W2
Control Number: 264031
Date of Preparation:
February 3, 2011
Date of Revision :
September 1, 2022
Jamp - ASA 81 mg EC Page 2 of 46
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
........................................................................................................
7
DRUG INTERACTIONS
........................................................................................................
7
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE.....................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
....................................................................11
STORAGE AND STABILITY
...............................................................................................13
DOSAGE FORMS, COMPOSITION AND
PACKAGING......................................................13
PART II: SCIENTIFIC INFORMATION
.........................................................................
14
PHARMACEUTICAL INFORMATION
................................................................................14
CLINICAL
TRIALS................................................................
Lestu allt skjalið
